Structural and functional identification of the pituitary adenylate cyclase-activating polypeptide receptor VPAC2 from the frog Rana tigrina rugulosa.

Recently, a frog pituitary adenylate cyclase-activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) receptor (fPVR) has been characterized, and interestingly, this receptor exhibits characteristics of both mammalian PACAP type II receptors VPAC(1)R and VPAC(2)R. In order to investigate the receptors responsible for mediating the actions of VIP and PACAP in amphibians, in this report, a frog VPAC(2) receptor (fVPAC(2)R) cDNA was isolated. fVPAC(2)R shares 47.7, 46.9 and 62.5% amino acid sequence identity with fPVR, human VPAC(1)R and human VPAC(2)R respectively. Functionally, fVPAC(2)R, when expressed in CHO cells, was responsive to both frog peptides including VIP, PACAP38 and PACAP27 where the EC(50) values of these peptides in intracellular cAMP production were 0.15, 0.18 and 0.16 microM respectively. The pharmacological profiles of human peptides (VIP, PACAP38 and peptide histidine methionine) to stimulate frog and human VPAC(2)Rs were compared, and it was found that these peptides could only activate the frog receptor at micromolar concentrations. fVPAC(2)R was found to be widely distributed in various peripheral tissues as well as several regions of the brain. The presence of the receptor transcripts suggests the functional roles of the receptor in mediating the actions of PACAP and/or VIP in these tissues. As VIP and particularly PACAP27 are highly conserved peptides in vertebrate evolution, comparative studies of these peptides and their receptors in non-mammalian vertebrates should provide clues to better understand the physiology of these important peptides in human and other vertebrates.

[1]  H. Marston,et al.  Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Annick Thomas,et al.  Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist , 2000, The Journal of Biological Chemistry.

[3]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. , 2000, Pharmacological reviews.

[4]  E. Ekblad.  Pharmacological evidence for both neuronal and smooth muscular PAC1 receptors and a VIP-specific receptor in rat colon , 1999, Regulatory Peptides.

[5]  I. Gozes,et al.  Pharmaceutical VIP: prospects and problems. , 1999, Current medicinal chemistry.

[6]  S. Mojsov,et al.  Functional studies of a glucagon receptor isolated from frog Rana tigrina rugulosa: implications on the molecular evolution of glucagon receptors in vertebrates , 1999, FEBS letters.

[7]  S. Fleetwood-Walker,et al.  VIP and PACAP: very important in pain? , 1999, Trends in pharmacological sciences.

[8]  H. Vaudry,et al.  A Cloned Frog Vasoactive Intestinal Polypeptide/ Pituitary Adenylate Cyclase-Activating Polypeptide Receptor Exhibits Pharmacological and Tissue Distribution Characteristics of Both VPAC1 and VPAC2 Receptors in Mammals. , 1999, Endocrinology.

[9]  A. Couvineau,et al.  Site‐Directed Mutagenesis of Human VIP1 versus VIP2 Receptors , 1998, Annals of the New York Academy of Sciences.

[10]  I. Huhtaniemi,et al.  Vasoactive intestinal peptide is an important endocrine regulatory factor of fetal rat testicular steroidogenesis. , 1998, Endocrinology.

[11]  B. Chow,et al.  Molecular evolution of vertebrate VIP receptors and functional characterization of a VIP receptor from goldfish Carassius auratus. , 1997, General and comparative endocrinology.

[12]  E. Goetzl,et al.  Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. , 1997, American journal of respiratory cell and molecular biology.

[13]  S. Mojsov,et al.  Multiple Human Receptors for Pituitary Adenylyl Cyclase‐Activating Polypeptide and Vasoactive Intestinal Peptide Are Expressed in a Tissue‐Specific Manner a , 1996, Annals of the New York Academy of Sciences.

[14]  A. Couvineau,et al.  Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. , 1996, Biochemistry.

[15]  T. Usdin,et al.  PACAP acts through VIP type 2 receptors in the rat testis , 1995, Neuropeptides.

[16]  B. Rusak,et al.  Neuropeptides phase shift the mammalian circadian pacemaker , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  H. Vaudry,et al.  Frog vasoactive intestinal polypeptide and galanin: primary structures and effects on pituitary adenylate cyclase. , 1995, Endocrinology.

[18]  A. Couvineau,et al.  Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. , 1995, Biochemical and biophysical research communications.

[19]  J. Goossens,et al.  Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. , 1994, Biochemical and biophysical research communications.

[20]  T. Bonner,et al.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.

[21]  M. Feuilloley,et al.  Pituitary adenylate cyclase-activating polypeptide stimulates both adrenocortical cells and chromaffin cells in the frog adrenal gland. , 1994, Endocrinology.

[22]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[23]  H. Onda,et al.  Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. , 1993, Biochemical and biophysical research communications.

[24]  G. Fink,et al.  The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide , 1993, FEBS letters.

[25]  J. Christophe,et al.  Type I receptors for PACAP (a neuropeptide even more important than VIP?). , 1993, Biochimica et biophysica acta.

[26]  S. Wank,et al.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Goetzl,et al.  Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. , 1993, Biochemical and biophysical research communications.

[28]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[29]  H. Mikawa,et al.  Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells , 1992, Clinical and experimental immunology.

[30]  S. Said.  Vasoactive intestinal polypeptide (VIP) in lung function and disease. , 1991, Nihon Kyobu Shikkan Gakkai zasshi.

[31]  H. Vaudry,et al.  Primary structure of frog pituitary adenylate cyclase-activating polypeptide (PACAP) and effects of ovine PACAP on frog pituitary. , 1991, Endocrinology.

[32]  Y. Kaziro,et al.  Molecular cloning and expression of a cDNA encoding the secretin receptor. , 1991, The EMBO journal.

[33]  E. Goetzl,et al.  Cloning and expression of the human vasoactive intestinal peptide receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  N. Minamino,et al.  Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). , 1990, Biochemical and biophysical research communications.

[35]  M. Culler,et al.  Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. , 1989, Biochemical and biophysical research communications.

[36]  P. Hof,et al.  Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain , 1987, Neuroscience.

[37]  C. Ottaway.  Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. , 1987, Immunology.

[38]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[39]  W. Rostène,et al.  Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system , 1986, Brain Research.

[40]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[41]  J. Waschek,et al.  Characterization and messenger ribonucleic acid distribution of a cloned pituitary adenylate cyclase-activating polypeptide type I receptor in the frog Xenopus laevis brain. , 2000, Endocrinology.

[42]  T. Voisin,et al.  Receptors for Peptides of the VIP/PACAP and PYY/NPY/PP Families , 1999 .

[43]  P. Robberecht,et al.  Characterization of the VIP receptor from SUP T1 lymphoblasts. , 1996, Advances in neuroimmunology.

[44]  M. Giembycz,et al.  Airways Smooth Muscle: Peptide Receptors, Ion Channels and Signal Transduction , 1995, Respiratory Pharmacology and Pharmacotherapy.

[45]  B. Chow,et al.  Immunohistochemical Demonstration of PACAP in the Pituitary, PACAP Stimulation of Growth Hormone Release from Pituitary Cells, and Molecular Cloning of Pituitary Type I PACAP Receptor* , 2022 .